Novedades

• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs
• Revlimid (lenalidomide) generics launch across Europe

Investigación

• Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
• Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
• Impact of e-bidding procurement on generic omeprazole injection prices in Thailand
• Trajectories of prices in generic drug markets

General

• Crecimiento de medicamentos genéricos en Brasil y Venezuela
• Penetración de los medicamentos genéricos en México y Brasil
• FDA releases one-year progress report for the Generic Drug Cluster
• Empresas de fabricación de productos farmacéuticos en Brasil

Novedades

• EC approval of natalizumab, aflibercept and tocilizumab biosimilars
• EMA recommends approval of first ustekinumab biosimilar Uzpruvo
• FDA approves first interchangeable ustekinumab biosimilar Wezlana
• Alvotech biosimilars: FDA ustekinumab application rejection; adalimumab interchangeability designation re-submission

Investigación

• Switches between biosimilars and their reference products
• Latin America's biosimilars market: regulatory, institutional, and technological aspects
• Impact of trastuzumab biosimilars use in metastatic HER2-positive breast cancer
• Biosimilar anti-VEGF: transforming retina treatment economics in South Asia

General

• Canada’s Prince Edward Island adopts biosimilars switching policy
• ASCO policy statement on biosimilars and interchangeables in oncology updated
• Biosimilars approved in Japan
• Fomento al desarrollo de productos biosimilares en Puerto Rico

• Latin American Forum
• Fármacos complejos no biológicos
• Enfoque por país

• Directrices
• Políticas y legislación
• Informes

• Congresos
• Artículos patrocinados
• Enlaces patrocinados